Azizi Fereidoun, Abdi Hengameh, Amouzegar Atieh, Habibi Moeini Ali Siamak
Endocrine Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Endocrine Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Best Pract Res Clin Endocrinol Metab. 2023 Mar;37(2):101631. doi: 10.1016/j.beem.2022.101631. Epub 2022 Feb 24.
Thionamide antithyroid drugs (ATD) are the treatment of choice for Graves' hyperthyroidism. The major drawback of ATD treatment for 1-2 years is the relapse of hyperthyroidism in about 50% of patients. Recently, it has been shown that ATD treatment for more than five years is accompanied by long-term remission in majority of patients without additional major side effects in both adults and children. Compared to radioactive iodine therapy, long-term ATD results in more favorable outcomes. This review summarizes the evidence on long-term ATD therapy regarding the remission rate of hyperthyroidism, efficacy and safety, indications and mode of therapy in patients with hyperthyroidism.
硫酰胺类抗甲状腺药物（ATD）是格雷夫斯甲亢的首选治疗药物。ATD治疗1 - 2年的主要缺点是约50%的患者会出现甲亢复发。最近有研究表明，ATD治疗超过五年时，大多数患者可实现长期缓解，且成人和儿童均无额外的严重副作用。与放射性碘治疗相比，长期使用ATD可带来更有利的结果。本综述总结了关于长期ATD治疗在甲亢患者中的甲亢缓解率、疗效和安全性、适应证及治疗方式的相关证据。
